Catalyst is thrilled to welcome a distinguished panel of experts for a discussion on innovative clinical trial approaches to advance Cell & Gene Therapy (CGT) products for patients with rare diseases.

 Joining us are Dr. Kiran Musunuru (University of Pennsylvania), a leading voice in Cell & Gene Therapy and a pioneer in base editing; Dr. PJ Brooks (NIH), a distinguished thought leader in the generation of streamlined GT development platforms; and Dr. Jeff Allen (Friends of Cancer Research), an esteemed oncology expert and passionate patient advocate.

 Moderated by Catalyst, this session will convene key stakeholders from industry, research, and patient communities to examine how innovative clinical trial designs can be more effectively leveraged for CGTs to meet the needs of the rare disease community. We’ll highlight lessons learned from the oncology field, strategies for shaping platform designations, applications of umbrella and basket trials, and opportunities emerging under the new FDA administration. 

 Join us for this dynamic conversation on Monday, June 16th, from 2:15–3:15 PM at DIA. We’d love to connect if you’ll be attending!